CYP19A1 and Glucose intolerance: We found that SERT deletion or pharmacological inhibition suppresses ovarian Cyp19a1 expression, reducing circulating 17β-estradiol levels, leading to abnormal fat accumulation, insulin resistance, and glucose intolerance.